Foreign-Trade Zone (FTZ) 43-Battle Creek, Michigan; Notification of Proposed Production Activity; Pfizer, Inc. (Nirmatrelvir Active Pharmaceutical Ingredient (API) for COVID-19 Treatment); Kalamazoo, Michigan

CourtForeign-trade Zones Board
Citation87 FR 11410
Record Number2022-04225
Published date01 March 2022
Federal Register, Volume 87 Issue 40 (Tuesday, March 1, 2022)
[Federal Register Volume 87, Number 40 (Tuesday, March 1, 2022)]
                [Notices]
                [Page 11410]
                From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
                [FR Doc No: 2022-04225]
                -----------------------------------------------------------------------
                DEPARTMENT OF COMMERCE
                Foreign-Trade Zones Board
                [B-6-2022]
                Foreign-Trade Zone (FTZ) 43--Battle Creek, Michigan; Notification
                of Proposed Production Activity; Pfizer, Inc. (Nirmatrelvir Active
                Pharmaceutical Ingredient (API) for COVID-19 Treatment); Kalamazoo,
                Michigan
                 Pfizer, Inc. (Pfizer) submitted a notification of proposed
                production activity to the FTZ Board for its facility Kalamazoo,
                Michigan. The notification conforming to the requirements of the
                Board's regulations (15 CFR 400.22) was received on February 22, 2022.
                 Pursuant to 15 CFR 400.14(b), FTZ production activity would be
                limited to the specific foreign-status materials/components and
                specific finished product described in the submitted notification
                (summarized below) and subsequently authorized by the Board. The
                benefits that may stem from conducting production activity under FTZ
                procedures are explained in the background section of the Board's
                website--accessible via www.trade.gov/ftz. The proposed finished
                product and materials/components would be added to the production
                authority that the Board previously approved for the operation, as
                reflected on the Board's website.
                 The proposed finished product is Nirmatrelvir API (duty rate,
                6.5%).
                 The proposed foreign-status materials and components include
                Registered Starter Chemical PF-04349713-01, Registered Starter Chemical
                PF-07321787, Registered Starter Chemical PF-07328614-01, 2-
                Hydroxypyridine-N-oxide (HOPO), and Dimethylaminopropylethyl
                carbodiimide hydrochloride (EDC HCI) (duty rates are 3.7% or 6.5%). The
                request indicates that certain materials/components are subject to
                duties under Section 301 of the Trade Act of 1974 (Section 301),
                depending on the country of origin. The applicable Section 301
                decisions require subject merchandise to be admitted to FTZs in
                privileged foreign status (19 CFR 146.41).
                 Public comment is invited from interested parties. Submissions
                shall be addressed to the Board's Executive Secretary and sent to:
                [email protected]. The closing period for their receipt is April 11, 2022.
                 A copy of the notification will be available for public inspection
                in the ``Online FTZ Information System'' section of the Board's
                website.
                 For further information, contact Diane Finver at
                [email protected].
                 Dated: February 23, 2022.
                Elizabeth Whiteman,
                Acting Executive Secretary.
                [FR Doc. 2022-04225 Filed 2-28-22; 8:45 am]
                BILLING CODE 3510-DS-P
                

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT